Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
复制标题
肝细胞癌患者传统经动脉化疗栓塞术后持续反应持续时间与生存率的关系
DOI：
10.1001/jamanetworkopen.2018.3213
复制
发表时间：
2018-10-01
影响因子：
13.8
通讯作者：
Peng, Zhenwei
中科院分区：
文献类型：
--
作者：
Zhang, Yaojun;Zhang, Mengping;Peng, Zhenwei
关键点问题：肝细胞癌患者常规经动脉化疗栓塞后的总生存期（OS）是否有一个早期可靠的替代终点？结果在这项对中国2734例患者的队列研究中，发现6个月或更长的持续反应时间与化疗栓塞后5年OS的相关性最强。持续缓解时间≥ 6个月是影响OS的独立预后因素。这意味着持续缓解时间≥ 6个月与OS相关，可作为常规经动脉化疗栓塞治疗中晚期肝癌的早期替代终点。
Key Points Question Is there an early reliable surrogate end point for overall survival (OS) in patients with hepatocellular carcinoma after conventional transarterial chemoembolization? Findings In this cohort study of 2734 patients in China, sustained response duration of 6 months or more was found to have the strongest association with 5-year OS after chemoembolization. Sustained response duration of 6 months or more was found to be the independent prognostic factor for OS. Meaning Sustained response duration of 6 months or more was associated with OS and may serve as an early surrogate end point after conventional transarterial chemoembolization for intermediate hepatocellular carcinoma.